|
Volumn 33, Issue 2 Suppl 2, 2014, Pages
|
Tumor necrosis factor inhibitors in psoriasis: an update.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADALIMUMAB;
CERTOLIZUMAB PEGOL;
GOLIMUMAB;
IMMUNOGLOBULIN F(AB) FRAGMENT;
IMMUNOGLOBULIN G;
INFLIXIMAB;
MACROGOL DERIVATIVE;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR RECEPTOR;
ARTICLE;
DRUG ANTAGONISM;
HUMAN;
IMMUNOGENICITY;
PSORIASIS;
PSORIASIS TREATMENT;
TNF;
TUMOR NECROSIS FACTOR INHIBITORS;
IMMUNOGENICITY;
PSORIASIS TREATMENT;
TNF;
TUMOR NECROSIS FACTOR INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
IMMUNOGLOBULIN G;
POLYETHYLENE GLYCOLS;
PSORIASIS;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTORS;
MLCS;
MLOWN;
|
EID: 84905573639
PISSN: 10855629
EISSN: None
Source Type: Journal
DOI: 10.12788/j.sder.0070 Document Type: Article |
Times cited : (10)
|
References (0)
|